Farhad Ravandi

68.3k citations
1.3k papers · 34.7k · 7 hit papers · h-index 90

Impact in

  • Hematology top 0.01%
    • Acute Myeloid Leukemia Research
    • Chronic Myeloid Leukemia Treatments
    • Hematopoietic Stem Cell Transplantation
  • Genetics top 0.01%
    • Chronic Lymphocytic Leukemia Research
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

  • Hematology 1.1k
    • Acute Myeloid Leukemia Research 768
    • Chronic Myeloid Leukemia Treatments 469
    • Multiple Myeloma Research and Treatments 93
  • Genetics 591
    • Chronic Lymphocytic Leukemia Research 394
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 183
Co-authors
Hagop M. Kantarjian (251 shared papers)Jörge E. Cortes (251 shared papers)Guillermo Garcia‐Manero (251 shared papers)Elias Jabbour (251 shared papers)Gautam Borthakur (251 shared papers)Susan O’Brien (251 shared papers)Tapan M. Kadia (251 shared papers)Stefan Faderl (237 shared papers)
Journals
Blood (543 papers)Journal of Clinical Oncology (151 papers)Cancer (96 papers)American Journal of Hematology (62 papers)British Journal of Haematology (26 papers)
Partner nations
United StatesGermanyFrance

In The Last Decade

Farhad Ravandi

1.2k papers receiving 34.2k citations

Farhad Ravandi's Hit Papers

Acute myeloid leukemia: current progress and future directions 2021 · 471 citations
4710+6+13Years since publication2505007501000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2021 Blood Cancer Journal
  2. 2021 Cancer
  3. 2020 Cancer Discovery
  4. 2020 JAMA Oncology
  5. 2012 Journal of Clinical Oncology
  6. 2006 Blood
  7. 2006 Cancer

Peers

Farhad Ravandi
Comparison fields: 5 of 153
  • Hematology 24.8k
  • Genetics 10.4k
  • Public Health, Environmental and Occupational Health 9.3k
  • Oncology 7.5k
  • Molecular Biology 13.0k
Replace Guillermo Garcia‐Manero with:
Guillermo Garcia‐Manero United States
Pierre Fenaux France
Martin S. Tallman United States
Stefan Faderl United States
Frederick R. Appelbaum United States
Elias Jabbour United States
Clara D. Bloomfield United States
Francis J. Giles United States
Susan O’Brien United States
Deborah A. Thomas United States
Farhad Ravandi relative to Guillermo Garcia‐Manero United States Guillermo Garcia‐Manero's profile →
Citations per field
00.5×1.5×
Guillermo Garcia‐Manero · 1×
Citations per year

Countries citing papers authored by Farhad Ravandi

Since Specialization
Citations

This map shows the geographic impact of Farhad Ravandi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farhad Ravandi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farhad Ravandi more than expected).

Fields of papers citing papers by Farhad Ravandi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farhad Ravandi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farhad Ravandi. The network helps show where Farhad Ravandi may publish in the future.

Co-authors

The 25 scholars most cited alongside Farhad Ravandi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Farhad Ravandi Line = papers co-authored together Farhad Ravandi links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 1.3k papers — load more, or switch the sort, to bring in the rest.

#Work
1
Decitabine improves patient outcomes in myelodysplastic syndromes
Cancer ·Hagop M. Kantarjian, Jean‐Pierre J. Issa, C Rosenfeld, John M. Bennett, Maher Albitar, John F. DiPersio, Virginia M. Klimek, James L. Slack, Carlos de Castro Lozano, Farhad Ravandi, Richard E. Helmer, Lanlan Shen, Stephen D. Nimer, Richard D. Leavitt, Azra Raza, Hussain I. Saba
Hit paper breakdown →		20061139
2
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Journal of Clinical Oncology ·Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska, Agnieszka Wierzbowska, Grzegorz Mazur, Jiří Mayer, Jyh-Pyng Gau, Wen‐Chien Chou, Rena Buckstein, Jaroslav Čermák, Ching-Yuan Kuo, Albert Oriol, Farhad Ravandi, Stefan Faderl, Jacques Delaunay, Daniel Lysák, Mark D. Minden, Christopher Arthur
Hit paper breakdown →		2012818
3
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Blood ·Hagop M. Kantarjian, Yasuhiro Oki, Guillermo Garcia‐Manero, Xuelin Huang, Susan O’Brien, Jörge E. Cortes, Stefan Faderl, Carlos E. Bueso‐Ramos, Farhad Ravandi, Zeev Estrov, Alessandra Ferrajoli, William G. Wierda, Jianqin Shan, Jan Davis, Francis J. Giles, Hussain I. Saba, Jean‐Pierre J. Issa
Hit paper breakdown →		2006515
4
Acute myeloid leukemia: current progress and future directions
Blood Cancer Journal ·Hagop M. Kantarjian, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Gautam Borthakur, Elias Jabbour, Guillermo Garcia‐Manero, Marina Konopleva, Farhad Ravandi
Hit paper breakdown →		2021471
5
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
Blood ·Guillermo Garcia‐Manero, Hagop M. Kantarjian, Blanca Sánchez‐González, Hui Yang, Gary L. Rosner, Srđan Verstovšek, Michael Rytting, William G. Wierda, Farhad Ravandi, Charles Koller, Lianchun Xiao, Stefan Faderl, Zeev Estrov, Jörge E. Cortes, Susan O’Brien, Elihu H. Estey, Carlos Bueso-Ramos, Jackie Fiorentino, Elias Jabbour, Jean‐Pierre J. Issa
2006380
6
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Cancer ·Hagop M. Kantarjian, Susan O’Brien, Farhad Ravandi, Jörge E. Cortes, Jianqin Shan, John M. Bennett, Alan F. List, Pierre Fenaux, Guillermo Sanz, Jean‐Pierre J. Issa, Emil J. Freireich, Guillermo Garcia‐Manero
2008345
7
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
The Lancet Oncology ·Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen, Elias Jabbour, Partow Kebriaei, Michael Rytting, Sergernne York, Farhad Ravandi, Monica Kwari, Stefan Faderl, Mary Beth Rios, Jörge E. Cortes, Luis Fayad, Robert Tarnai, Sa A. Wang, Richard Champlin, Anjali S. Advani, Susan O’Brien
2012309
8
Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
Journal of Clinical Oncology ·Deborah A. Thomas, Susan O’Brien, Stefan Faderl, Guillermo Garcia‐Manero, Alessandra Ferrajoli, William G. Wierda, Farhad Ravandi, Srđan Verstovšek, Jeffrey L. Jorgensen, Carlos E. Bueso‐Ramos, Michael Andreeff, Sherry Pierce, Rebecca Garris, Michael J. Keating, Jörge E. Cortes, Hagop M. Kantarjian
2010301
9
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
Blood ·Andres O. Soriano, Hui Yang, Stefan Faderl, Zeev Estrov, Francis J. Giles, Farhad Ravandi, Jörge E. Cortes, William G. Wierda, Souzanne Ouzounian, Andrés Quezada, Sherry Pierce, Elihu H. Estey, Jean‐Pierre J. Issa, Hagop M. Kantarjian, Guillermo Garcia‐Manero
2007297
10
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Blood ·Hagop Kantarjian, Farhad Ravandi, Susan O’Brien, Jörge E. Cortes, Stefan Faderl, Guillermo Garcia‐Manero, Elias Jabbour, William G. Wierda, Tapan M. Kadia, Sherry Pierce, Jianqin Shan, Michael A. Keating, Emil J. Freireich
2010295
11
Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
American Journal of Hematology ·Courtney D. DiNardo, Caitlin R. Rausch, Christopher B. Benton, Tapan M. Kadia, Nitin Jain, Naveen Pemmaraju, Naval Daver, Wendy Covert, Kayleigh Marx, Morgan Mace, Elias Jabbour, Jörge E. Cortes, Guillermo Garcia‐Manero, Farhad Ravandi, Kapil N. Bhalla, Hagop M. Kantarjian, Marina Konopleva
2017293
12
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Blood ·Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald, Michelle A. Rudek, Trivikram Rajkhowa, Mary Ann Richie, Sherry Pierce, Naval Daver, Guillermo Garcia‐Manero, Stefan Faderl, Aziz Nazha, Marina Konopleva, Gautam Borthakur, Jan A. Burger, Tapan M. Kadia, Sara Dellasala, Michael Andreeff, Jörge E. Cortes, Hagop M. Kantarjian, Mark J. Levis
2013290
13
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Journal of Clinical Oncology ·Farhad Ravandi, Jörge E. Cortes, Daniel M. Jones, Stefan Faderl, Guillermo Garcia‐Manero, Marina Konopleva, Susan O’Brien, Zeev Estrov, Gautam Borthakur, Deborah A. Thomas, Sherry R. Pierce, Mark Brandt, Anna Byrd, B. Nebiyou Bekele, Keith W. Pratz, Rajyalakshmi Luthra, Mark J. Levis, Michael Andreeff, Hagop M. Kantarjian
2010282
14
Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
Journal of Clinical Oncology ·Farhad Ravandi, E Estey, Dan Jones, Stefan Faderl, Susan O’Brien, Jackie Fiorentino, Sherry Pierce, Deborah Blamble, Zeev Estrov, William G. Wierda, Alessandra Ferrajoli, Srđan Verstovšek, Guillermo Garcia‐Manero, Jörge E. Cortes, Hagop M. Kantarjian
2008270
15
A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies
Clinical Cancer Research ·Francis J. Giles, Thomas Fischer, Jörge E. Cortes, Guillermo Garcia‐Manero, Joachim Beck, Farhad Ravandi, Eric Masson, P. Rae, Glen Laird, Sunil Sharma, Hagop M. Kantarjian, Margaret Dugan, Maher Albitar, Kapil N. Bhalla
2006264
16
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia
Blood ·William G. Wierda, Susan O’Brien, Xuemei Wang, Stefan Faderl, Alessandra Ferrajoli, Kim‐Anh Do, Jörge E. Cortes, Deborah A. Thomas, Guillermo Garcia‐Manero, Charles Koller, Miloslav Beran, Francis J. Giles, Farhad Ravandi, Susan Lerner, Hagop M. Kantarjian, Michael J. Keating
2007252
17
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
The Lancet Oncology ·Koichi Takahashi, Feng Wang, Hagop M. Kantarjian, Doss Denaha, Kanhav Khanna, Erika J. Thompson, Li Zhao, Keyur P. Patel, Sattva S. Neelapu, Curtis Gumbs, Carlos E. Bueso‐Ramos, Courtney D. DiNardo, Simona Colla, Farhad Ravandi, Jianhua Zhang, Xuelin Huang, Xifeng Wu, Felipe Samaniego, Guillermo Garcia‐Manero, P. Andrew Futreal
2016251
18
Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment
Journal of Clinical Oncology ·Roland B. Walter, Megan Othus, Gautam Borthakur, Farhad Ravandi, Jörge E. Cortes, Sherry Pierce, Frederick R. Appelbaum, Hagop Kantarjian, Elihu H. Estey
2011244
19
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia
Blood ·Farhad Ravandi, Susan O’Brien, Deborah Thomas, Stefan Faderl, Dan Jones, Rebecca Garris, Samuel Dara, Jeffrey L. Jorgensen, Partow Kebriaei, Richard E. Champlin, Gautam Borthakur, Jan A. Burger, Alessandra Ferrajoli, Guillermo Garcia‐Manero, William G. Wierda, Jörge E. Cortes, Hagop M. Kantarjian
2010244
20
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Cancer Discovery ·Nicholas J. Short, Marina Konopleva, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Courtney D. DiNardo, Naval Daver
Hit paper breakdown →		2020243

About Farhad Ravandi

Farhad Ravandi is a scholar working on Hematology, Genetics, Public Health, Environmental and Occupational Health, Molecular Biology and Oncology, having authored 1.3k papers that have together received 34.7k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (768 papers), Chronic Myeloid Leukemia Treatments (469 papers), Acute Lymphoblastic Leukemia research (406 papers), Chronic Lymphocytic Leukemia Research (394 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (183 papers), Histone Deacetylase Inhibitors Research (127 papers), Lymphoma Diagnosis and Treatment (107 papers) and Multiple Myeloma Research and Treatments (93 papers). The work is most often cited by research in Hematology (24.8k citations), Genetics (10.4k citations), Public Health, Environmental and Occupational Health (9.3k citations), Oncology (7.5k citations) and Molecular Biology (13.0k citations). Farhad Ravandi has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Guillermo Garcia‐Manero, Elias Jabbour, Gautam Borthakur, Susan O’Brien, Tapan M. Kadia, Stefan Faderl, Marina Konopleva and Naval Daver. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, American Journal of Hematology and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guillermo Garcia‐ManeroBreakdown of academic impact, for papers by Pierre FenauxBreakdown of academic impact, for papers by Martin S. TallmanBreakdown of academic impact, for papers by Stefan FaderlBreakdown of academic impact, for papers by Frederick R. AppelbaumBreakdown of academic impact, for papers by Elias JabbourBreakdown of academic impact, for papers by Clara D. BloomfieldBreakdown of academic impact, for papers by Francis J. GilesBreakdown of academic impact, for papers by Susan O’BrienBreakdown of academic impact, for papers by Deborah A. Thomas